Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities

被引：81
作者：
De Paepe, P.
De Wolf-Peeters, C.
机构：
[1] Catholic Univ Louvain, Dept Pathol, Div Morphol & Mol Pathol, B-3000 Louvain, Belgium
[2] AZ St Jan AV, Dept Pathol, B-8000 Brugge, Belgium
来源：
LEUKEMIA | 2007年 / 21卷 / 01期
关键词：
DLBCL; classification; morphology; microarray; immunohistochemistry;
D O I：
10.1038/sj.leu.2404449
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Diffuse large B-cell lymphoma (DLBCL) as defined by the World Health Organization (WHO) classification is clinically, morphologically and genetically a heterogeneous group of malignant proliferations of large lymphoid B cells. Over the last 6 years, several studies have been published improving our understanding of these lymphomas. These studies analyzed DLBCL by their gene expression profile, provided further information on some of the variants of DLBCL listed in the WHO classification and stressed the impact of the site of origin of these tumors. This review summarizes these recent data and explores their impact on the recognition of new clinicopathological lymphoma entities.
引用
收藏
页码：37 / 43
页数：7
相关论文
共 67 条
[1]   Histiocyte-rich, T-cell-rich B-cell lymphoma: a distinct diffuse large B-cell lymphoma subtype showing characteristic morphologic and immunophenotypic features [J].
Achten, R ;
Verhoef, G ;
Vanuytsel, L ;
De Wolf-Peeters, C .
HISTOPATHOLOGY, 2002, 40 (01) :31-45
[2]   T-cell/histiocyte-rich large B-cell lymphoma: A distinct clinicopathologic entity [J].
Achten, R ;
Verhoef, G ;
Vanuytsel, L ;
De Wolf-Peeters, C .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1269-1277
[3]   A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation [J].
Adam, P ;
Katzenberger, T ;
Seeberger, H ;
Gattenlöhner, S ;
Wolf, J ;
Steinlein, C ;
Schmid, M ;
Müller-Hermelink, HK ;
Ott, G .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2003, 27 (11) :1473-1476
[4]   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].
Alizadeh, AA ;
Eisen, MB ;
Davis, RE ;
Ma, C ;
Lossos, IS ;
Rosenwald, A ;
Boldrick, JG ;
Sabet, H ;
Tran, T ;
Yu, X ;
Powell, JI ;
Yang, LM ;
Marti, GE ;
Moore, T ;
Hudson, J ;
Lu, LS ;
Lewis, DB ;
Tibshirani, R ;
Sherlock, G ;
Chan, WC ;
Greiner, TC ;
Weisenburger, DD ;
Armitage, JO ;
Warnke, R ;
Levy, R ;
Wilson, W ;
Grever, MR ;
Byrd, JC ;
Botstein, D ;
Brown, PO ;
Staudt, LM .
NATURE, 2000, 403 (6769) :503-511
[5]  
[Anonymous], 2001, Pathology and Genetics of Haematopoietic and Lymphoid Tissues
[6]  
ATKINS CD, 1994, NEW ENGL J MED, V330, P574
[7]  
Banham AH, 2005, CLIN CANCER RES, V11, P1065
[8]  
Banham AH, 2001, CANCER RES, V61, P8820
[9]   Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome [J].
Barrans, SL ;
Fenton, JAL ;
Banham, A ;
Owen, RG ;
Jack, AS .
BLOOD, 2004, 104 (09) :2933-2935
[10]   Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma [J].
Barrans, SL ;
Carter, I ;
Owen, RG ;
Davies, FE ;
Patmore, RD ;
Haynes, AP ;
Morgan, GJ ;
Jack, AS .
BLOOD, 2002, 99 (04) :1136-1143
1234567